fatty acid binding protein 4/5 inhibitors (Merck)

N/A

Report date: 2025/03/18 20:00:05
NME

Base Information

Drug Namefatty acid binding protein 4/5 inhibitors (Merck)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFatty acid-binding protein, adipocyte inhibitorsFatty acid binding protein 5 inhibitors
TargetsFatty acid binding protein 5Fatty acid-binding protein, adipocyte
Therapy Area/IndicationsMetabolic Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMerck Research Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Research Laboratories
Active IndicationsN/A
Inactive IndicationsMetabolic Syndrome

Other Information

ATC CodeN/A
Related LinksN/A